Investors

2017 Press Releases

Webcast ImageWebcast
GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting (Live)
12/11/17 at 8:15 p.m. ET
GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting
Monday, December 11, 2017 8:15 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/11/17GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program
-- Highlights Include Compassionate Access Case Studies, Pediatric Pharmacokinetic Data and Burden of Care Data -- -- Company Plans to Announce Top-Line Data from Part A of Phase 3 HOPE Study in First Half of 2018 -- -- Company to Host Investor Webcast Today, Monday, December 11, at 8:15 p.m. ET/5:15 p.m. PT to Discuss SCD Program -- SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced results from six data pre... 
Printer Friendly Version
12/09/17GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)
Data to be Highlighted in ASH Press Briefing and Company to Host Investor Webcast on Monday, December 11, at 8:15 p.m. ET/5:15 p.m. PT to Discuss Data SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 (GLOBE NEWSWIRE) --    Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of once-daily oral therapy, voxelotor (previously called GBT440), a potentially disease-modifying therapy for adolescents with sickle cell disease (SCD). The... 
Printer Friendly Version
11/30/17Global Blood Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the compensation committee of the Company’s board of directors granted two new employees inducement grants. The first employee received an option to purchase 15,000 shares of the Company’s common stock with a per share exercise price of $39.25, the closing trading price on the grant date of November 28, 2017. The second employee received an option to purchas... 
Printer Friendly Version
11/13/17Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
Based on DSMB Review, Patients Age 12 to 17 Can Now be Enrolled in Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced today that the independent Data and Safety Monitoring Board (DSMB) for the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study evaluating voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD), has completed its first sch... 
Printer Friendly Version
11/07/17Global Blood Therapeutics Announces Participation at the Stifel 2017 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the Stifel 2017 Healthcare Conference in New York City on Tuesday, November 14, 2017 at 2:00 p.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a clinical-stage biopharmac... 
Printer Friendly Version
11/02/17Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the third quarter ended September 30, 2017. “We continue to make important progress toward our goal of bringing GBT440, now known by the non-proprietary name voxelotor, to patients of all ages as a potentially disease-modifying therapeutic option in sickle cell disease,” said Ted W. Love, M.D., president and chief execut... 
Printer Friendly Version
11/01/17Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual Meeting
Results from HOPE-Kids 1 Study Expanded Dose Cohort Selected for Inclusion in ASH Press Program Company to Host Investor Webcast on Monday, December 11 SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that new data supporting the clinical development of voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD) will be presented during the 59th American Society of Hematology (ASH) Annu... 
Printer Friendly Version
10/28/17Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic Anemia
Data Presented at Sickle Cell Disease Association of America (SCDAA) 45th Annual National Convention SOUTH SAN FRANCISCO, Calif., Oct. 28, 2017 (GLOBE NEWSWIRE) --  Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study in which a patient with sickle cell disease (SCD) who was ineligible to participate in GBT’s ongoing Phase 3 HOPE study of voxelotor (previously called GBT440) due to severe, transfusion-refractory anemia received the investigation... 
Printer Friendly Version
10/24/17Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the World Health Organization (WHO) has approved “voxelotor” (pronounced vox-el’-oh-tor) as the International Nonproprietary Name (INN) for its lead product candidate GBT440, and that the United States Adopted Name Council has adopted “voxelotor” as the United States Adopted Name (USAN) for GBT440. Voxelotor is an oral, once-daily therapy that is designed to mo... 
Printer Friendly Version
10/23/17Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program
Three Proof-of-Concept Studies Support GBT440 Mechanism of Action and Safety Profile  Clinically Meaningful Efficacy Results Not Achieved in Patients with IPF Data Supports Ongoing GBT440 Program in Sickle Cell Disease Conference Call and Webcast Today at 8:30 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the discontinuation of its GBT440 program for the treatment of idiopathic pulmonar... 
Printer Friendly Version
10/11/17Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
First Presentation of Data Specifically Focused on HbSC Genotype Data Presented at Academy for Sickle Cell and Thalassemia (ASCAT) 11th Annual Conference SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study highlighting the effect of GBT440 on markers of anemia and hemolysis (the destruction of red blood cells) in a patient with sickle cell disease (SCD) with the variant HbSC genot... 
Printer Friendly Version
10/03/17Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that new data supporting its GBT440 program in sickle cell disease (SCD) will be presented in October at the Academy for Sickle Cell and Thalassemia (ASCAT) 11th Annual Conference in London and the Sickle Cell Disease Association of America (SCDAA) 45th Annual National Convention in Atlanta. "Each of the two GBT440 presentations in October will highlight an importan... 
Printer Friendly Version
09/26/17Global Blood Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on September 25, 2017, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 15,000 shares of the Company’s common stock with a per share exercise price of $28.25, the closing trading price on the grant date, and a restricted stock unit award for 10,000 shares of the Company’s common stock, in each case u... 
Printer Friendly Version
09/06/17Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
Healthcare Providers, Patient Advocates, Government Agencies and Industry Will Discuss Critical Issues Facing SCD Community During National Sickle Cell Disease Awareness Month Livestream of Conference Will Be Available Through Collaboration with Sickle Cell Warriors SOUTH SAN FRANCISCO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will host the Annual Sickle Cell Disease (SCD) Therapeutics Conference, which will take... 
Printer Friendly Version
09/05/17Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to GBT440 for the treatment of sickle cell disease (SCD). GBT440 is being developed as a potentially disease-modifying therapy for SCD. “The FDA’s Rare Pediatric Disease designation for GBT440, in addition to the previously granted Orphan Drug and Fast Track designati... 
Printer Friendly Version
08/30/17Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the following investor conferences in September: 12th Annual Wells Fargo Securities Healthcare Conference in Boston on Wednesday, September 6, 2017 at 10:50 a.m. Eastern Time (ET); Morgan Stanley Global Healthcare Conference in New York City on Wednesday, September 13, 2017 at 11:40 a.m. ET; and Cantor Fitzgerald Global Healthcar... 
Printer Friendly Version
08/09/17Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 2017 Wedbush PacGrow Healthcare Conference in New York City on Wednesday, August 16 at 10:55 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a clinical-stage biopha... 
Printer Friendly Version
08/07/17Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the second quarter ended June 30, 2017. "Regulatory authorities in the U.S. and EU are increasingly working to address the need for new treatment options for sickle cell disease or SCD. We support these efforts and remain committed to working collaboratively with the SCD community to bring a new and potentially disease-mod... 
Printer Friendly Version
07/26/17Global Blood Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that on July 24, 2017, the compensation committee of the Company’s board of directors granted one new employee an option to purchase 30,000 shares of the Company’s common stock with a per share exercise price of $30.25, the closing trading price on the grant date, and a restricted stock unit award for 25,000 shares of the Company’s common stock, in each case under t... 
Printer Friendly Version
07/10/17Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population
SOUTH SAN FRANCISCO, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it has expanded the ongoing HOPE-KIDS 1 Study (GBT440-007), a Phase 2a open-label study of GBT440 in pediatric patients with sickle cell disease (SCD), to include a new single-dose cohort in children age 6 to 11. “Following positive pharmacokinetic and safety results from the single-dose cohort of adolescent patients age 12 to 17, which were recently present... 
Printer Friendly Version
06/28/17Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)
– GBT440 is First Potential Treatment for SCD To Be Accepted for PRIME – – PRIME Designation Allows for Frequent and Early Interactions with the Agency Aimed at Assisting Accelerated Evaluation and Approval – SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the European Medicines Agency (EMA) has determined that GBT440 for the treatment of sickle cell disease is eligible for its Priority Medicines (PRIME)... 
Printer Friendly Version
06/23/17Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of preliminary results from the single-dose adolescent (age 12 to 17) cohort of the ongoing HOPE-KIDS 1 Study, a Phase 2a open-label study of GBT440 in adolescents with sickle cell disease (SCD). The results, which demonstrated that the pharmacokinetics of GBT440 are similar in adolescents and adults, were presented at the 22nd Congress of the Europ... 
Printer Friendly Version
06/06/17Global Blood Therapeutics Announces Participation at the Goldman Sachs 38th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will present at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, Calif. on Tuesday, June 13 at 3:20 p.m. Pacific Time. The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a... 
Printer Friendly Version
05/18/17Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association’s 22nd Congress
SOUTH SAN FRANCISCO, Calif., May 18, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that new data supporting its GBT440 program in sickle cell disease (SCD) will be presented at the upcoming 22nd Congress of the European Hematology Association (EHA), which will be held June 22-25, 2017 in Madrid. The poster presentation will highlight preliminary results from the single dose arm of the ongoing HOPE-KIDS 1 Study, a Phase 2a open-label study of GBT440... 
Printer Friendly Version
05/01/17Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the first quarter ended March 31, 2017. "We continue to make important progress advancing our lead product candidate, GBT440, across both our sickle cell disease (SCD) and idiopathic pulmonary fibrosis (IPF) indications,” said Ted W. Love, M.D., president and chief executive officer of GBT. “We are focused on activating n... 
Printer Friendly Version
03/29/17Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 29, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will present at the 16th Annual Needham Healthcare Conference in New York, NY on Wednesday, April 5 at 12:10 p.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors section. About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a clinical-stage biopharm... 
Printer Friendly Version
03/13/17Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today reported business progress and financial results for the fourth quarter and year ended December 31, 2016. "2016 was a year of consistent execution and rapid advancement across both of our GBT440 clinical programs designed to treat diseases where the patient communities are greatly underserved. This was highlighted by coming to agreement with the FDA on the design of our p... 
Printer Friendly Version
03/01/17Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March
SOUTH SAN FRANCISCO, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will present at the following investor conferences in March: Cowen and Company 37th Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2017 at 8:40 a.m. Eastern Time (ET); and The 29th Annual ROTH Conference in Dana Point, CA on Tuesday, March 14, 2017 at 4:30 p.m. Pacific Time (PT). The presentations will be webcast live and ava... 
Printer Friendly Version
02/27/17Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced the closing of its previously announced underwritten public offering of 5,867,347 shares of its common stock at a price to the public of $24.50 per share, which includes 765,306 additional shares of ... 
Printer Friendly Version
02/22/17Global Blood Therapeutics Prices a $125.0 Million Upsized Common Stock Public Offering
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced the pricing of its upsized underwritten public offering of 5,102,041 shares of its common stock at a price to the public of $24.50 per share. The gross proceeds to GBT from the offering, before deduc... 
Printer Friendly Version
02/21/17Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat grievous blood-based disorders with significant unmet need, today announced an agreement to sell $75.00 million in shares of its common stock in a registered underwritten public offering. In addition, GBT has granted the underwriter a 30-day option to purchase up to $11.25 m... 
Printer Friendly Version
02/16/17Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced initiation of the Phase 1 Basecamp (GBT440-011) clinical trial, which is evaluating the physiologic effects of GBT440 in fit healthy volunteers under hypoxic conditions and exercise conditions that maximally stress the function of the heart and lungs. GBT440 is a hemoglobin modifier that left-shifts the oxygen-hemoglobin dissociation curve, which has the potentia... 
Printer Friendly Version
02/14/17Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that a paper describing the discovery of GBT440 and its ability to bind to hemoglobin and prevent red blood cells from sickling was published online in ACS Medicinal Chemistry Letters, a peer-reviewed publication of the American Chemical Society. GBT440 is in Phase 3 development as a potentially disease-modifying therapy for sickle cell disease (SCD). The publicatio... 
Printer Friendly Version
01/18/17Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced enrollment of the first patient in the HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study, a pivotal Phase 3 clinical trial of GBT440 in people with sickle cell disease (SCD). The HOPE Study will be conducted at leading SCD sites globally and is expected to enroll up to 400 adults and adolescents with SCD who have had at least one episo... 
Printer Friendly Version
01/03/17Global Blood Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 3 p.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.  The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.globalbloodtx.com in the Investors & Media section. About Global Blood The... 
Printer Friendly Version